-- alzheimer's? is there a link between the delirium you sometimes see it older people after an operation that involves a general anesthetic and dementia? dr. hodes: there is good data to a couple of points. the first weather delirium can be succeeded or followed by decreasing cognitive function and progression of dementia, the answer appears to bs. but so also for general anesthesia, even if there's not delirium. often after general anesthetic, there can be a short-term decline in cognitive function, most people recover fine, but the failure to recover rosalie quickly is also predictive of long-term decline. both of these from the results of deep anesthesia or delirium you seem to be capable of accelerating the functional decline. senator collins: dr. peterson? dr. peterson: i agree, it also has to do with cognitive reserve. sometimes with people who are developing dementia of one kind or another and then undergo general anesthesia, they may have a lower threshold for becoming delirious in that cont

alzheimer's disease by 2025. to meet that goal, the chairman of the advisory committee on alzheimer's research care and services, dr. ron peterson, whom we will hear from shortly, told our committee last congress that we will need to devote at least $2 billion a year to alzheimer's research. well, at first blush that may seem like a lot of money. but when you compare it to that $226 billion that we're spending caring for people with alzheimer's, it's less than 1%. and that's the context that we need to put it in. and that's why i've introduced a resolution with several of my colleagues stating that the senate will strive to double the amount of funding that our country spends on alzheimer's in fiscal year 2016 and develop a plan to meet the target of $2 billion over the next five years. this afternoon, or perhaps tomorrow, the budget is on the floor today, i also will be offering an amendment to the budget, which i'm pleased to say is co-sponsored by my ranking member, senator mccaskill, as well as senator warner

alzheimer's is not cheap. what i saw there that last night was a team. i saw a group of people from the deep south to the far west from the heartland of america to new england all looking each other in the eyes and saying you know what? we're at the tipping point and we're going to push this thing over. so i come here today to tell you i don't believe in big government. i believe in good government and know that what's happening in this committee is going change the face of the alzheimer's community. last night, i sat at a table with 10 other people and there was a young boy there. his name was tyler. and while we were talking about all the things that were going on and we were listening to the author of the book "still alice." as i was looking at him, the only thing i could think of is here is a 12 or 13-year-old if i said to him right now what is a cassette deck, he would go huh? if i said to him what is an 8-track? he would go what? i want that young man, that young boy tyler, to when his kids are his age,

it was alzheimer's.ereat was as an only child caring for a single mother the world we had shared with stowe lager and add that 38 had a new world that was foreign to me. after her diagnosis we didn't receive much information on what to do next. a friend recommended looking on line for health benefits of the alzheimer's association which is the first time a light began to shied. a concern about the disease with the diagnosis meant and what the next deaths should be for her care. also how to cope with the emotions i was feeling is important because that was only compounded by the stress of a stowe were. and back pain was so severe the old doctor recommended a make a lifestyle change to reintegrate own health. exercise three times a week and have been eating a healthier diet but the emotional part is very difficult maritime receiver mother feels like day number one in every single time. when she was diagnosed she was living alone and exhibited other warning signs that raised concerns about her safety. and t

according to the alzheimer's association, we will spend $226 billion caring for people with alzheimer's this year. and by the year 2050, the yearly cost will be more than $1.1 trillion. now, when the director of the national institute of mental health testified in front of the health committee during last congress, he noted that if we can prevent or even delay the onset of dementia, we can save billions of dollars. he also said that this is really a matter of choosing to invest in research now or choosing to pay up in a big way later on. clearly congress is choosing to pay up in a big way later on. congress has reduced the purchasing power of the n.i.h. by nearly 25% and last year n.i.h. spent only $562 million on alzheimer's disease research. that's about .2% of what the disease cost us last year. dr. hodes can you tell us very briefly how the reduction in support for n.i.h. funding affected the ability of you and your colleagues to advance research on alzheimer's? richard: thank you, senator warren for the question. it's certainly the case that progress in alzheimer's research is not

alzheimer's disease by 2025.meet that goal, the chairman of the advisory committee on alzheimer's research care and services, dr. ron peterson, whom we will hear from shortly told our committee last congress that we will need to devote at least $2 billion a year to alzheimer's research. well, at first blush that may seem like a lot of money. but when you compare it to that $226 billion that we're spending caring for people with alzheimer's, it's less than 1%. and that's the context that we need to put it in. and that's why i've introduced a resolution with several of my colleagues stating that the senate will strive to double the amount of funding that our country spends on als himmers in fiscal year 2016 and develop a plan to meet the target of $2 billion over the next five years. this afternoon, or perhaps tomorrow, the budget is on the floor today i also will be offering an amendment to the budget, which i'm pleased to say is co-sponsored by my ranking member, senator mccaskill, as well as senator warner, sena

for example not only just alzheimer's disease but what we call mixed dementias in which alzheimer's andsay dementia due to multiple strokes can coexist. in that case, the component due to alzheimer's will still be responsive to this drug. >> sreenivasan: so given that there have been other attempts at this how significant is this sort of advancement? >> well, this is the first drug of any class aimed at amyloid that has shown any convincing signal. so not only have there been antibody trials, but also there are small molecules pills, that are being tested that are aimed at the enzymes that make amyloid, for example. none of those have succeeded so far. so in terms of what we call the amyloid hypothesis of alzheimer's, that amyloid is key to the cause of the disease, this is really important in terms of focusing or sort of confirming that that is a valid target. >> sreenivasan: so why is this particular drug or this particular type of therapy different? >> this is a biologicallal. it's a protein, what's called a monocolonial antibody, and it's directed specifically at this molecule that

sperling lost her grandfather to alzheimer's.lene has watched her sister, who has the disease, and her mother who died because of it, both suffer anguishing declines. >> i just couldn't deal with the the-- your mother doesn't know who you are. >> reporter: and now your sister. >> my sister now has it, and she's only six years older than i am. i used to say to my kids, figet this disease, shoot me because it's horrible to watch someone go through it. >> reporter: an important study released today from the mayo clinic identifies a different toxic protein called tau as the likely cause of alzheimer's. scott, most researchers believe that tau and amyloid are connected, and the a4 study has now been expanded to track the buildup of both in the brains of these patients. >> pelley: wyatt andrews in washington wyatt, thanks very much. four years after catastrophe japan is building a tsunami wall. that's next. (ee-e-e-oh-mum-oh-weh) (hush my darling...) (don't fear my darling...) (the lion sleeps tonight.) (hush my darling...) man snoring

alzheimer's. "bottom line" continues in a moment. ♪ mark: welcome back. nike posted third-quarter profits that the estimates. one reason, his performance in north america. sales rose 6% and orders for delivery are likely to rise 15% between now and july. first-quarter sales beat estimates at one of the nation's biggest homebuilders. rose profit margins fell because of higher land and construction costs. the average price of a house rose 8%. shares of kb home's have been up as much as 6%. simon property group is making its best and final offer for macerich. the price, $23 billion. macerich said the earlier offer seriously undervalued the company. coming up at 2:24 p.m. tiffany's profits and the surging u.s. dollar. focus on the future of luxury and labor. shares of biogen sword into a record high today after the copy reported that an early-stage trial showed positive reports test results for its experimental -- positive results for its experimental alzheimer's drug. good to have you on. is this a p

bell calmeyer is with the alzheimer's association. >> there's over 100 clinical trials happening nowrecruiting for enrollees and that's super important. >> there have been no new treatments for alzheimer's in the past decade. neil and judy believe this research could help preserve their precious memories. andrea roane, wusa9. >> more than a half million dollars was spent last year on alzheimer's research alone. >>> new research from the american heart association shows many hispanic americans at high risk for cardiovascular disease. in a study that tracked more than 500 hispanic americans experts found nearly 78% were considered metabolically unhealthy meaning they either have high blood pressure, high blood sugar or both. those risk factors were also found to have an even bigger effect on the hardened arteries than obesity does. experts call for more nutrition and exercise programs within the latino community. >>> nine very lucky d. c. students hit the college lottery. they got a surprise visit from the president of gw university. >> he bond by their schools without warning to offer

>> this is the first evidence that we can modify the progression of alzheimer's. and i think that's very encouraging indeed. >> reporter: researchers tested the treatment on 166 people who had mild alzheimer's or early signs of dementia. some got a placebo, others got different doses of the drug. those who received the highest dosage had the slowest build-up of brain-clogging plaques linked to alzheimer's. they also performed better on memory tests. >> for the first time, people with mild changes in memory but not frank alzheimer's disease were included. they were able to maintain their thinking and continue to live independently. >> reporter: there were some side effects, headaches and brain swelling. and experts caution this was a small initial study. >> in order for us to really see if there's value, you have to do it much larger groups, like thousands of individuals. >> reporter: the drug does now move on to larger trials. but even if everything goes well and the drug is judged to be safe and effective, lester, it would be several years before it would be avai

a number expected to triple by 2050 according to the alzheimer's association. it's currently the sixth leading cause of death in the united states. and there are no drugs on the market shown to slow the disease's course. >> even with reasonable penetration numbers, this could, with a straight face be a $10 billion drug. >> reporter: that's $10 billion a year. analysts are also looking closely at the drug's safety. it did show a side effect known as aria or abnormal regular imaging. it will be important to see if biogen can administer high enough dose without raising safety risks. stock rose 40% since data from september and we could see big swings tomorrow. eric smith at callan estimates could drop 20% if disappointing though he's optimistic about the results. the stock could gain 15% if the results are stellar, making this one of the most anticipated events for the entire biotech industry this year. for "nightly business report," i'm meg tirrell. >> to read more about biogen's experimental alzheimer's drug, head to our web site nbr.com. >>> menards with a sign

dad saw the doctor a lone when he was put on alzheimer's drug.ut nothing was explained to the family who was worried about his memory trouble. >> i think with dad he left the office and he forgot about it he may not have wanted to share it because he was afraid. >> there are laws called hipaa that prevent doctors from talking about patients unless the patient greece. that's why families are advised to get involved and ask questions. there is no cure for alzheimer's but when detector early it can sometimes be slowed and patients and their families can have time to make plans. >> i have a lot of anger and now i think i also have a lot of sadness because i always wonder how much better could he be? could could we have helped sooner. >> now it's a waiting game for carol and her family who can't figure out why the doctor wasn't more forthcoming. >> one of the most common reasons they're worried about causing emotional distress. >> and doctors say it's difficult to explain a complicateed fatal disease in the limited time given for appointments. there's

the exact cause is unknown but people with alzheimer have what is described as a build up of plaque in and stopping neurons from working property and the university have treated this in mice using ultrasound waves and said it completely cleared the plaque in 75% of the mice and then performed better in memory tests. and jeremy hughes is the chief executive of the uk and says more work needs to be done before a treatment is passed. >> we are excited every time there is a bit of research that shows possible home for people with alzheimer's disease and over 40 million people around the world living with the disease today with little prospect yet of really kinding a cure this is early stage research we are hearing about from australia and only been done on mice it's a relatively small study and hopeful with more investment and research and double the efforts we will be able to build on some early studies and really find the answer in years to come so yes it's important to have hope for the future but of course what is also supporting is living with alzheimer's today and people around the w

the experimental drug that's showing promise in the fight against alzheimer's. our market monitor no matter what. all that and more for "nightly business report," friday march 20th. going in spring fever came to wall street today. dow jones industrial average capped a strong week within striking distance of all-time record closing high. blue chip index up to 18,127. the nasdaq gained 34 points rising for 5 straight days to get third highest close ever at 5026. and s&p 500 up nearly 19 to 2108. in a week of big triple digit swings don't fight the fed. stocks got lot of help after the fed wednesday dropped the word patient from its interest rate prognosis but basically said it will be patient about raising them. the dow rose 2% for the week. the nasdaq outpacing the others with a 3% rise and the s&p. so its steepest weekly advance. but focus squarely this week on nasdaq that closed above 5,000 for the second time this year and on a few occasions this week the index was up when the dow and the s&p were down. so why the recent strength in the index? bertha coombs ha

almost 50 million people live with alzheimers which causes severe memory loss.re is no cure although medication can slow the progression. the exact cause is unknown but people with alzheimers have plaques in their brains which stop neurorons from working prop everly, researchers have treated this in mice, using ultrasound waves. and it did clear the plaque in 75% of the mice who then performed better in memory tests. jeremy hughes says the findings are good news. >> while we are excited every time there's a bit of research that shows possible hope for people without alzheimers disease, and as you say, there are over 40 million people around the world living with with the disease today. with little prospect yet of really finding a cure this is early stage research that we are hearing about it has only been done on mice, we are very hope that have with more investment in research, and doubles efforts we will be able to build on these early studies and find the answers in the years to come, so yes it is important to have hope, but what is also important is to give

when added to another alzheimer's treatment, like aricept® it may improve overall function and cognition and may slow the worsening of symptoms for a while.

. >> still head, new hope for alzheimer's patients. the new drug that could slow memory loss. >>> plus, bart versus beer. why the transit agency is suing a brewery. >>> a bart beer bat sell brewing. bart is suing 5050 brewery over this bart beer. barrel aged really tasty is the acronym. bart is also an acronym for bay area rapid transit. this has sparked the trade mark lawsuit. bay area rapid transit said quote use of the bart name by unauthorized party for commercial game whether or not they are in the rapid transit business is a violation of trade mark law and something bart must protect itself against. we will keep you posted on that battle. >>> a new experimental drug is showing promising results for people in the early stages of alzheimer's. drug maker biogen released findings today. it shows the drug may slow memory loss in alzheimer's patience when the disease is still in a mild stage and reduces the plaque in the brain associated with alzheimer's. a much larger study is needed to confirm the results. >> call it an extreme case

the color purple represents the alzheimer's movement. it is my hope that someday soon the color purple will also represent those who survive alzheimer's. [applause] and we are going to keep the record open until friday come april 3, so maybe additional testimony or information for the record is part of this. i would like to thank all of my advocates who are here today and everyone who participated in today's hearing, including my staff who has worked hard to share a commitment. this concludes the hearing and i would like to thank you for being here. [applause] [applause] [inaudible conversations] [inaudible conversations] [inaudible conversations] >> coming up on c-span2, a hearing of the tsa prescreening program followed by the state treasures of tennessee and washington state on the fiscal health of state. and later the awards dinner. >> on the next "washington journal" lieutenant colonel james talks about the desertion trial against bowe bergdahl. and california representative loretto sanchez come a member of the armed services and ho

and new hope in the fight against alzheimer's disease. >> we begin in the u.s. where authorities are search forgive those hyped the shooting of two police officers in the city much ferguson missouri. they have called it defenseless and repugnant. it's just hours after the police chief resigned following a report of widespread abuse within the police department. we're live in ferguson watching all of the developments. what is the latest, kristen on the investigation? >> well, county police are investigating the shooting that tack place right behind me outside of the city police department. they're also in charge of policing the demonstrators outside of the police department as well. on the investigation front they've been questioning suspects, questioning people, but they say at this point they do not have have any one charge. they have not named the suspect as of yet. the situation outside of the police department is much calmer than it was a short time ago. the demonstrators were back out in force. they mostly have gone home for the night now but they were in t

in fact, 2 out of every 3 people who will have alzheimer's is a woman.o not only are they the most likely to be in fact diagnosed with alzheimer's, typically are the caregivers. and when you look at the research that's being done, it's miniscule in reference to cancer research. and when you look at the federal government and how much is being spent to provide health care through medicare, it's something like $200 billion a year. by 2050, it's going to be over $1 trillion a year just for alzheimer's care. so we've got to put more money into research so we can find a cure to alzheimer's. >> the conference is something you founded 26 years ago. you're not even old enough to have founded that. >> okay. >> it's so amazing. i've had the great privilege of being there for so many years. why did you feel the need to do that? >> well, first of all, thank you for being such a great supporter or sponsor of this. i did it because i thought a woman needs a place to mnetwork to find new career goals. women will come up to all of us, so many -- everyone on the board is

people didn't talk much about alzheimer's. nobody seemed to know much about it so i wrote a children's book and then i did a report that reported for the first time that alzheimer's was a woman's disease and i was that helm of the women's conference and we did a lot on care giving and alzheimer's and i saw more and more women looking for answers, saying it was impacting them. >> you are the executive producer of still alice, are you encouraged by the fact it was getting so much publicity when it comes to spreading the word? >> i am excited it is so successful. i am hoping the challenge will win an oscar for all these incredible researchers. that for me will be the ultimate oscar if we wipe out this disease. >> women make up 2/3 of patients and so many other are caring for loved ones who are effected. the challenge urges women to get educated and empowered to raise awareness and support for everyone dealing with alzheimer's. >>> a dog dropped off and abandon inside a bin for road kill, a growing problem at a bay area shelter. >

a new report by the alzheimer's association found only 45% of people with alzheimer's or their caregiversen the diagnosis by their doctors. >> the reason we're doing this is to show people not to it hide. you know, there's such a stigma attached to it. >> reporter: the goal of the registry is to increase the number of clinical trial volunteers especially in minority populations. smith went public with her diagnosis last june. do you remember the first dish you made? >> pineapple upside down cake. >> reporter: i remember from our last interview you said one of the first things you ever made was...? it was a cake. >> upside down cake. >> reporter: yes! but the disease is eroding her short-term memory and reasoning as shown by a terrifying incident last fall. a family member smith on a bus in new york city to return to their home in sag harbor, new york. gasby was waiting at the other end, but smith never showed. >> i was horrified because i know that after 24 hours the possibilities of not finding someone go up dramatically. >> reporter: it turns out, smith had gotten off the bus when it st

million americans have alzheimer's.ne of those are over 65 years old, and the majority are women but those that conducted the study point out that women tend to live longer than men. the study looked at disclosure rates and found most people were told they had alzheimer's when it was already advanced and that deprives the opportunity to seek care and early treatment by. by the year 20257 million americans are expected to have alzheimer's. >>> a warning for folks in fredericksburg. what the public works department is warning people to stay away from. >>> standing by for new information on the safety of maryland drivers. the report we're waiting for >>> 4:58 now. republican of all stripes are weighing in on texas senator ted cruz's bid for the white house. john cornen declined to endorse him. utah senator mike leigh who teamed up with cruz said he's not ready to endorse anyone. however, cruz will likely get big tea party support. he could make a splash if he wins the texas primary. he faces a huge potential roster of gop

-- cannot be a trigger for alzheimer's? is there a link when you see something in older people after an operation that involves a general anesthetic and dementia? dr. hodes: good point. the room can be succeeded or followed by decreasing the cognitive function and so also for general anesthesia, even if there is not delirium so that is after general anesthetics, there can be a short-term decline. most people recover fine, but the recovering quickly is also predicted of long-term. both of these insoles, whatever that means to the brain as a result of deep anesthesia or delirium, do seem to be capable of a celebrating that functional decline -- of accelerating the functional decline. madam chairman: dr. peterson? dr. peterson: if the brain is injured, how much resilience doesn't have to respond? sometimes people who are developing dementia and undergo anesthesia may have a lower threshold for becoming delirious in that context. it may contribute to the downward decline, but it also may just be a stress test on a system that i

from alzheimer's and autism to schizophrenia and traumatic brain injury. nih is also innovating in translational science for basic science findings are developed in clinical benefits. let me give you a few examples. recent advances in technology have led to the discovery of more than 1,000 risk factors for disease. but drug development is a terribly difficult and failure-prone business. a major reason for failures is that scientists often just don't know how to choose the right pathways to target for the next generation of drugs that they want to develop. so with this in mind, we were excited just a year ago to launch the accelerating medicines partnership, or amp. this is an unprecedented precompetitive, public-private partnership using cutting-edge scientific approaches to choose the most promising targets for therapeutic intervention. besides nih, amp partners include importantly the fda, ten biopharmaceutical firms and a number of nonprofits, including patient advocacy groups. initially, amp is focusing on three disease areas that are ripe for discover

with alzheimer's. this disease is going to bankrupt the medicare and the medicaid programs. we're currently spending $154 billion from those two programs for care of patients with alzheimer's. so that's one of the amendments that i will be proposing. i see the senator from illinois is on the floor who has been another real leader in this area. mr. durbin: would the senator from maine yield for a question? ms. collins: yes i would be happy to yield. mr. durbin: first let me thank you. i took a look at the 200 pending amendments on this budget resolution. i think ten, at least ten relate to biomedical research from both sides of the aisle. this is clearly a bipartisan issue. and i thank you for speaking out on this alzheimer's issue because they came this week to visit with us, and it is stunning just stunning to think for a moment that we diagnose a person with alzheimer's in america once every 68 seconds. when my staff told me that, i couldn't believe it. i said that's got to be wrong. it's right. it's

a famous face joins the fightzh against alzheimer's. >> i'm b.th, and i suffer from alzheimer's disease. >> pelley: and a bus takes an unexpected detour when the cbs evening news continues. apples fall, but the apples of your cheeks don't have to. defy gravity. juvÉderm voluma® is the only fda-approved injectable gel to instantly add volume to your cheek area. as you age, cheeks can lose volume. voluma adds volume creating contour and lift for a more youthful profile. for up to two years. temporary side effects include tenderness, swelling, firmness lumps, bumps, bruising, pain redness, discoloration and itching. ask your doctor. juvÉderm voluma®. defy gravity. it tastes better when you grow it. it tastes even better when you share it. it's not hard, it's doable. it's growable. get going with gro-ables. miracle-gro. life starts here. ufferers. one tried the newest allergy spray which could take several days to feel the full effect of relief. the other took claritin-d which starts to work on allergies with nasal congestion in 30 minutes. the moral

. >>> and, happy memories fading a new report says an alarming number of alzheimer's patients are not being told they have the disease. health reporter stephanie stahl tells us why so many families are being kept in the dark. >>> and it is last weekend in march but it feels more like february carol returns with the latest on this spring chill we will be right back. ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪ great rates for great rides. geico motorcycle see how much you could save. >>> back now on "eyewitness news" crews are working to clear the massive pile of debris, from the gas explosion, and building collapse in new york city, they are carefully removing every part of the three century old buildings that came crashing down in the east village on thursday. the medical examiner's office a along with the nypd's k-9 unit are also assisting. they have not found the two missing people, one of the survivors lost a cat in the fire. >> the air conditioner i have face nothing to the air shaft for our apartment got knocked out of the window into their window started to break smoke started filling the room, i kept

shares of biogen soaring, promising alzheimer's drug.and biotech investors with esquared asset management but begin with you just upped your price target on biogen to 512 from 410. why did you do it and what makes you so confident biogen will have the revenue and earnings from this drug that will justify it? >> if you look at biogen the company, the base business will grow almost 20% in the next three years. the company's trading at 21 times next year's number. it's very reasonable for growth stock. as you know. many much less attractive posting almost no growth at all and a solid pipeline. a lot of data over the next 12 months. important data in alzheimer's. the target price, based on multiple. next year's number reasonable and stock up from here. >> i can understand how you got to the price target. justify the 20 times multiple? that's catching my ear. 25 times is not a low multiple. for a company of biogen's size particularly. >> if you look you know historically, these company, trading at 30 times, when they post 20% growth. there's

as alzheimers patients occurred with age. but seeing the globe for 20 years old. sometimes it doesn't correspond to the symptoms but there is a strong suspicion the cells are are weakened and by the time he is 80 years old nerve cells begin to die. >> is there a way to test the protein in a living patient? >> it attacks the brain in a specific area. right here. and you can see the a trophy and death of the nerve cells and that can go to alzheimers not in itself. it may mean nothing and a red herring, but look at the clintical findings. >> you said it is a small study. is there an indication to help prevent alzheimers or is there a test doctors can g. >> who is the president. and who is the president. and going back wards tell me the last four presidents. seven from hundred and count back wards. 93, and 93 is 86. and it doesn't mean you have it. but these questions that doctors need to have. there is no one test or cat scan or mri that shoes that. you put the clinical picture together and come up with a diagnosis. >> it is scary. >> it is a small study but hopefull

. >>> plus, new hope for people suffering from alzheimer's.treatment being developed by scientists could actually help bring back old memory. music ♪ is this the year you spend more quality time with your dog? then make his day at bass pro shops' dog days event and sale. and get your boat ready for spring at bass pro shops' power pros service center. come see the power pros. >>> a toddler spent almost 14 hours strapped upside down in a car. the frigid water of the spanish fork river was just inches from her head. you're seeing video of the rescue right now. the newly released video shows merge responders pulling her out of that crash that ended up killing her mother. will carr is following the story from our west coast bureau, will? >> reporter: you're about to see why this little girl's dad says that it is a miracle that she is still alive. she was in a car that police believe hit a cement barrier on a bridge and flipped upside down and plunged down into a river where it sat for 14 hours before fishermen saw it and called 911. that's when vid

the alzheimer's dementia is $809 hiv is 3 billion which is 10% of budget. cbo just released and this will not show up well but our national debt which they say by 2025 will be 77% which they say is dangerous to our future. knowing that will go into pure of constrained resources because of our last six years as clay national debt, i would again push that if hiv as you mentioned a substantial address still problems that substantially and all sides, dementia is a balloon medicare and medicaid are just going to go bankrupt dealing with this. we should start shifting more aggressively resources from that which has been addressed to that which we are confronted. just making the point once more. i yield back. >> thank you, senator cassidy. senator whitehouse. >> thank you, chairman. thank you both for being here today. rhode island is a small state and we tend to have a lot of small and entrepreneurial companies. and i'm concerned that when there is fda or other regulatory disadvantage that a company must bear to bring a product online that it's a lot hard on a sm

this is about alzheimer's. when you talk about alzheimer's.y the year 2030, 75 million people will actually have alzheimer's and need effective treatment. they have found treatment now that does something never been done before. it is experimental drug. it reduces plaque that can be brain damaging, while at the same time, significantly slowing cognitive decline. so that is a great double dish. and that is why you're seeing this big move to the upside in a new high for biogen idec. back to you. melissa: nicole, thank you so much. i want to bring charles payne on this one. you've been pounding the table on this stock on your fabulous 6:00 p.m. program. >> yes. melissa: are you taking a victory lap. >> we'll take a victory lap and go further into biotechs. there are amazing biotech companies. we want to live without pain and agony. that is amazing. story nicole said so phenomenal. going straight from phase one to phase three. imagine how great life would be if we didn't have to worry about alzheimer's? melissa: charles payne thank you very much.

the last thing is alzheimer's is proving to be in creditably costly.6 we'll spend $26 billion to care for patients having that disease. it's something that needs to be addressed first and foremost. >> who's more at risk men or women? >> more women have it. two-thirds of people who have alzheimer's are women. there are a number of reasons for that. women live longer but also there could be life experiences. >> i have to say what surprised me mohs is some doctors are not telling their patients. >> the thinking is you don't want to upset them get them depressed. on the other hand what you're doing at the oechld the day is you're gipping the entire family from having that discussion oerl on to figure out what will you want later on down the line when you don't have the ability to reesend and you have to make decisions is when you come into the house. woe saw that that with our models. i said what are you going to do. she can still reason now. i said what about later on? she said well i don't like having people in the house. finally she said it would be oka

from alzheimer's and autism to schizophrenia and traumatic brain injury. nih is also innovating in translational science for basic science findings are developed in clinical benefits. let me give you a few examples. recent advances in technology have led to the discovery of more than 1,000 risk factors for disease. but drug development is a terribly difficult and failure-prone business. a major reason for failures is that scientists often just don't know how to choose the right pathways to target for the next generation of drugs that they want to develop. so with this in mind, we were excited just a year ago to launch the accelerating medicines partnership, or a.m.p. this is an unprecedented precompetitive, public/private partnership using cutting-edge scientific approaches to choose the most promising targets for therapeutic intervention. decides nih, a.m.p. partners include importantly the fda, ten biopharmaceutical firms and a number of nonprofits including patient advocacy groups. initially, a.m.p. is focusing on three disease areas that are ripe for d

wvo: caring for someone with alzheimer's means i am a lot of things. i am his guardian. i am his voice. so i asked about adding once-daily namenda xr to his current treatment for moderate to severe alzheimer's. it works differently. when added to another alzheimer's treatment, like aricept®, it may improve overall function and cognition. and may slow the worsening of symptoms for a while. vo: namenda xr doesn't change how the disease progresses. it shouldn't be taken by anyone allergic to memantine, or who's had a bad reaction to namenda xr or its ingredients. before starting treatment, tell their doctor if they have, or ever had a seizure disorder difficulty passing urine, liver, kidney, or bladder problems, and about any medications they're taking. certain medications, changes in diet, or medical conditions may affect the amount of namenda xr in the body... and may increase side effects. the most common side effects... are headache, diarrhea, and dizziness. wvo: all my life, he's protected me. now i am giving back. ask their doctor about adding... once-daily namenda xr